Journal Article (Review Article)

DZNE-2025-01131

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png New landscape of the diagnosis of Alzheimer's disease.

Frisoni, G. B. ; Hansson, O. ; Nichols, E. ; Garibotto, V. ; Schindler, S. E. ; van der Flier, W. M. ; Jessen, F.DZNE* ; Villain, N. ; Arenaza-Urquijo, E. M. ; Crivelli, L. ; Fortea, J. ; Grinberg, L. T. ; Ismail, Z. ; Minoshima, S. ; Ossenkoppele, R. ; Zetterberg, H. ; Petersen, R. C. ; Dubois, B.

2025
Elsevier London [u.a.]

This record in other databases:    

Please use a persistent id in citations: doi:10.1016/S0140-6736(25)01294-2

Abstract: Alzheimer's disease involves a drastic departure from the cognitive, functional, and behavioural trajectory of normal ageing, and is both a dreaded and highly prevalent cause of disability to individuals, and a leading source of health and social care expenditure for society. Before the advent of biomarkers, post-mortem examination was the only method available to establish a definitive diagnosis. In this first paper of the Series, we review state-of-the-art diagnostic practices and the typical patient journey in specialist settings, where clinicians engage in a differential diagnosis to establish whether Alzheimer's pathology (cerebral deposition of β-amyloid and hyperphosphorylated tau) is a contributor to cognitive impairment. Biomarkers indicating dysregulation of β-amyloid and tau homeostasis, measured with PET and cerebrospinal fluid analysis, allow a molecular-level diagnosis-a mandatory step in defining eligibility for the recently approved anti-amyloid treatments. We anticipate that easily accessible blood biomarkers, already available in some countries, will lead to a new diagnostic revolution and bring about major changes in health-care systems worldwide.

Keyword(s): Humans (MeSH) ; Alzheimer Disease: diagnosis (MeSH) ; Alzheimer Disease: cerebrospinal fluid (MeSH) ; Biomarkers: cerebrospinal fluid (MeSH) ; Biomarkers: blood (MeSH) ; Amyloid beta-Peptides: metabolism (MeSH) ; Amyloid beta-Peptides: cerebrospinal fluid (MeSH) ; tau Proteins: cerebrospinal fluid (MeSH) ; tau Proteins: metabolism (MeSH) ; Diagnosis, Differential (MeSH) ; Positron-Emission Tomography (MeSH) ; Biomarkers ; Amyloid beta-Peptides ; tau Proteins

---

Contributing Institute(s):

1. Clinical Alzheimer’s Disease Research (AG Jessen)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2025

---

Database coverage:
; ; ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 90 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---